Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 3/20 | 0.30 |
| ▸ | HTR2C | P28335 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29766636 | 1.00 | HIF1A (0.35) | HIF1ABRD4CREBBPATRHTR2A | |
| SCHEMBL26967784 | 0.76 | BRD4 (0.33) | HIF1ABRD4CREBBP | |
| SCHEMBL25897346 | 0.72 | DRD4 (0.33) | BRD4CREBBP | |
| SCHEMBL25897362 | 0.71 | IDO1 (0.40) | BRD4CREBBP | |
| SCHEMBL29766649 | 0.70 | ADRA2A (0.36) | HIF1AHTR2AHTR2C | |
| SCHEMBL25897315 | 0.70 | ADRA2A (0.36) | HIF1AHTR2AHTR2C | |
| SCHEMBL25897351 | 0.68 | — | — | |
| SCHEMBL30703392 | 0.68 | — | — | |
| SCHEMBL23087258 | 0.62 | PRMT5 (0.47) | HIF1AHTR2AHTR2C | |
| SCHEMBL31375980 | 0.60 | KMT2A (0.37) | HIF1AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117377669-A | TYK2 inhibitor and application thereof | 苏多生物科学有限公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-4294807-A1 | TYK2 INHIBITORS AND USES THEREOF | Sudo Biosciences Limited (GB) | 2023-12-27 | — | — | EP | disclosed |
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | TYK2, PDXK, JAK1 | HIF1A 2879/4885BRD4 73/4885CREBBP 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.